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ABSTRACT
Background: Guidelines recommend omalizumab in patients with uncontrolled severe allergic asthma. We
investigated real-life use of omalizumab, the proportion of patients fulfilling eligibility criteria, its costs and
its effectiveness.
Method: In a cohort of asthma patients initiating treatment with omalizumab in Belgium between 2010
and 2016, we investigated fulfilment of eligibility criteria (chronic use of high-dose inhaled corticosteroids
(ICSs) plus long-acting β2-agonists (LABAs) and ⩾2 severe asthma exacerbations in previous year), and
compared hospitalisations and systemic corticosteroid consumption in the year before and after
omalizumab initiation. We computed healthcare costs in the respective time periods and compared the
cost per prevented hospitalisation in patients fulfilling eligibility criteria versus those who did not.
Results: Between 2010 and 2016, omalizumab treatment was initiated in 2068 patients with asthma; only
24% fulfilled the eligibility criteria, mainly due to nonadherence to high-dose ICSs + LABAs. The
proportion of patients hospitalised for asthma decreased from 41% to 21% in eligible patients (absolute
risk reduction, 20%), whereas the absolute risk reduction was 5% (from 19% to 14%) in noneligible
patients. The cost per prevented hospitalisation was €44238 versus €139495, respectively. Chronic use of
systemic corticosteroids was discontinued in 35% of eligible patients versus 15% of noneligible patients.
Conclusion: In Belgium, omalizumab is mostly initiated in uncontrolled asthma patients who are
nonadherent to ICSs + LABAs. Omalizumab decreases hospitalisations and the use of systemic
corticosteroids, but at a high cost. Careful management of patients with difficult-to-treat asthma should be
a priority before prescribing omalizumab.
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Only 1 patient in 4 fulfils eligibility criteria for add-on treatment with omalizumab. Omalizumab
is effective but expensive, with the largest benefits if the eligibility criteria are met. Careful
asthma management is required before starting biologics. http://bit.ly/2ZJkzrq
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Introduction
Asthma is characterised by variable symptoms of shortness of breath, wheezing and cough, and affects
subjects of all age groups [1]. Asthma is a highly prevalent disease, since it affects up to 15% of children
and up to 8% of adults in countries with a western lifestyle [2, 3]. Exposure to allergens, pollutants and
viral infections can cause acute asthma exacerbations, which are characterised by increased symptoms and
require acute treatment with systemic corticosteroids [4, 5]. Severe asthma exacerbations can be
life-threatening, implying that patients need to be urgently treated and in most severe cases need to be
hospitalised. Besides the huge personal burden of asthma attacks, these exacerbations also induce
important direct medical costs as well as indirect costs (due to school or work absenteeism).
Inhaled corticosteroids (ICSs), either as monotherapy or in combination with long-acting bronchodilators,
such as long-acting β2-agonists (LABAs), are the mainstay of chronic treatment of asthma and aim to
control the disease [1]. According to the European Respiratory Society (ERS)/American Thoracic Society
(ATS) guidelines, severe asthma is currently defined as asthma that needs chronic treatment with
high-dose ICSs + LABAs (or another second controller) in order to obtain control, or asthma that remains
uncontrolled despite this treatment [6]. A subgroup of patients with severe asthma even requires chronic
treatment with oral corticosteroids on top of ICSs + LABAs. The Global Initiative for Asthma (GINA)
recommends add-on therapy with biologics in patients with uncontrolled severe asthma despite high-dose
ICSs (with LABAs) (GINA step 5). The choice of add-on monoclonal antibody depends on the underlying
phenotype of severe asthma; omalizumab is indicated in severe allergic asthma, whereas mepoluzimab,
reslizumab and benralizumab are indicated in severe eosinophilic asthma [7].
In classical randomised controlled trials, enrolling patients with excellent adherence, asthma becomes well
controlled in the majority of patients with mild-to-moderate disease. However, several observational
studies and surveys have demonstrated that, in real life, asthma is not well controlled in 25–40% of
patients [8]. Although many factors such as incorrect inhaler technique, active or passive smoking, and
comorbidities might contribute to lack of control in these “difficult-to-treat” patients with asthma, the
most important risk factor is nonadherence to controller therapy [6]. Discriminating between
difficult-to-treat asthma due to nonadherence and severe asthma despite adequate maintenance treatment
with high-dose ICSs + LABAs is critically important, as the former needs successful implementation of
appropriate ICS + LABA treatment, whereas the latter should be considered for add-on treatment with
biologics. Patients with severe allergic asthma and frequent exacerbations (⩾2 exacerbations in the last
12 months) might benefit from add-on treatment with omalizumab, a monoclonal antibody against
immunoglobulin E (IgE) [9, 10].
To investigate the characteristics of patients initiating treatment with omalizumab, and in particular
whether patients fulfilled eligibility criteria for omalizumab initiation, as well as to determine the real-life
effectiveness and cost of omalizumab, we performed a nationwide observational cohort study of adult
asthma patients receiving add-on treatment with omalizumab in the period from 2010 to 2016.
Methods
Data source
We defined a cohort of asthma patients initiating treatment with omalizumab between 2010 and 2016,
using claims data from the Belgian national social security department [11]. These claims data encompass
drug dispensing, medical services, hospitalisation and related costs. Information on dispensing included
the following: brand and generic name, strength, defined daily dose (DDD), dispensing date and
Anatomical Therapeutic Chemical (ATC) classification code [12, 13]. Information on indication of use and
underlying comorbidity was not available. In Belgium, affiliation with a social health insurance provider is
mandatory, implicating that we have data on all Belgian residents [11].
Study population
Data were gathered on medication and health service billed between January 1, 2010 and December 31,
2016. First, all dispensing data for omalizumab were extracted through a search on the ATC specific code,
R03DX05 [12]. Next, from the dispensing data, we identified patients with a first claim for omalizumab
between 2010 and 2016 and classified the date of first dispensing as the index date. A first claim means
that the patient had a first dispensing of omalizumab during the study period and no dispensing of
omalizumab in the year before. Omalizumab, as prescribed by a dermatologist, (≈indication chronic
idiopathic urticaria) was excluded. To investigate differences in asthma control before and after treatment
initiation, a subcohort was selected of all patients with at least 1 year of data before and after treatment
initiation. Patients initiating treatment in 2016 were excluded from this analysis as the study ended by
December 31, 2016.
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Covariates
Of all patients with a first dispensing of omalizumab, data were collected on 1) sex and age (at time of first
dispensing and categorised in age strata), and 2) sum of daily doses (DDs) of asthma drugs (ATC code
R03) in the 12 months preceding the first omalizumab dispensing [12, 13].
The DDD is the suggested maintenance dose per day for a drug when used for its main indication in
adults [12]. The number of DDDs per year, and per asthma drug, was presented by the median and 25th
and 75th percentiles. As the World Health Organization does not provide DDDs for fixed combinations of
ICSs and LABAs (ATC R03AK); the DD for fixed combinations refers to the dose as recommended in the
scientific notice. Asthma controller drugs consisted of ICSs with or without LABAs, leukotriene receptor
antagonists (LTRAs) or xanthines, and rescue therapy consisted of short-acting β2-agonists (SABAs) or
short-acting muscarinic antagonists (SAMAs) (table S1). Use of systemic corticosteroids (SCSs) of at least
180 DDDs in a period of 12 months was considered as maintenance therapy. In a sensitivity analysis,
chronic use of systemic steroids was defined as at least 90 DDDs in a period of 12 months.
To investigate the burden of asthma, the number of visits to the emergency department (ED) and the
number of hospitalisations (all combined with need of systemic corticosteroids), the number of outpatient
visits to a pulmonologist or other medical discipline, the national social health insurance expenses for
asthma drugs and the total health expenses were investigated in the 12 months preceding and the
12 months following the index date.
Fulfilling eligibility criteria to initiate treatment with omalizumab
According to GINA, anti-IgE (omalizumab) can only be added as a treatment step-up 5 in patients with
moderate-to-severe uncontrolled asthma, despite treatment with two or more controller medications [7].
A patient fulfilled eligibility criteria for omalizumab if the following criteria were met in the year preceding
the index date: 1) “Treatment with two or more controllers” defined as a patient for which at least 75% of
follow-up time was covered by the use of ICSs and LABAs (at least 274 DDs of ICSs and 274 DDs
of LABAs in the preceding 12 months); and 2) “uncontrolled asthma” defined as patients with
dispensing of SCSs, on at least two different occasions (with or without hospitalisation or an ED visit).
Omalizumab adherence and persistence
Treatment adherence to omalizumab was investigated by checking the number of omalizumab dispensings
over follow-up. A patient was considered to be omalizumab-compliant when the patient had at least
10 monthly dispensings of omalizumab out of 12 months of follow-up therapy. However, in Belgium,
4 months after the start of add-on treatment with omalizumab in patients with severe allergic asthma,
respiratory physicians need to re-evaluate the patients in order to determine the treatment response (very
good or good response versus insufficient response or asthma worsening). The treatment with omalizumab
is only continued (and further reimbursed) in patients who have a very good or good response after the
initial 4 months trial.
Effectiveness and cost of omalizumab
The effectiveness of omalizumab was investigated by comparing the number of asthma-related
hospitalisations and/or ED visits as well chronic systemic corticosteroid use in the year before and year
following treatment initiation.
The cost related to the use of omalizumab was assessed by comparing the cost of one prevented
hospitalisation, not only in the total population of patients with severe allergic asthma treated with
omalizumab, but also in stratified analysis of patients fulfilling or not fulfilling the eligibility criteria.
In addition, of all patients treated with omalizumab, expenses were captured with regard to costs of
asthma drugs (including omalizumab) and hospitalisations. Costs were compared in the 1 year before and
1 year after omalizumab initiation and expressed as mean annual cost per omalizumab-treated patient and
provided in strata of patients fulfilling or not fulfilling the eligibility criteria.
Mortality in patients with omalizumab
The mortality rate was expressed as the number of deaths in the 1 year following the index date divided by
the number of treated patients and expressed as number of deaths per 1000 omalizumab initiators in the
first year [14]. The standardised mortality ratio was calculated to compare the mortality in the 12 months
following treatment initiation to the mortality of the Belgian population, adjusting for age and sex [14].
Data analyses
Descriptive statistics were used to describe patient characteristics. Differences in proportion of asthma
burden before and after treatment initiation were investigated with the McNemar test, whereas differences
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in medians were tested using the Wilcoxon rank-sum test. The study was explorative and p-values were
used as descriptive measures. Data were analysed using SAS Enterprise Guide, version 5.1.
Results
During the study period 2010–2016, 3151 patients treated with omalizumab were identified, of which 2068
patients were identified as new users of omalizumab. The median age at treatment initiation was 50 years
and 56% were females.
Drug use in the 12 months preceding omalizumab initiation is presented in table 1. A total of 94% of
patients had used ICSs (with or without LABAs) in the 12 months preceding omalizumab initiation and
the median number of DDs (per year) for ICSs was 240. Overall, 89% of the ICS dispensing consisted of
fixed-dose combinations of ICSs with LABAs. Use of SCSs in the preceding 12 months was high (85%), of
which 31% used SCSs as maintenance therapy. With regard to the use of other asthma controller
therapies, 70% had used LTRAs in the preceding 12 months. Considering the asthma burden in the
12 months preceding omalizumab initiation, 24% of patients had been hospitalised or visited the ED, all in
combination with the need of SCSs (table 1).
Fulfilling eligibility criteria for add-on treatment with omalizumab
According to international asthma guidelines, treatment step-up with omalizumab is only indicated in
patients with severe uncontrolled asthma despite treatment with two or more controllers plus as-needed
reliever medication [7]. When investigating whether eligibility criteria were met, only 34% of patients were
on continuous use of ICSs and LABAs (defined as a at least 274 DDs in the preceding year) and only 24%
fulfilled the criteria of continuous use of ICSs and LABAs in combination with a history of ⩾2 severe
asthma exacerbations in the year (table 2) preceding treatment initiation.
Asthma burden before and after omalizumab initiation
Of the 2068 patients who initiated omalizumab, there were 1681 patients with at least 1 year of follow-up
data and still alive at 1 year following treatment initiation. Of these patients, we investigated the asthma
burden before and after omalizumab initiation (table 3). In patients initiating omalizumab, the number of
patients requiring ED visits or being hospitalised because of an asthma exacerbation decreased, with 2%
and 9% respectively (absolute risk reduction, p<0.001). The proportion of patients on chronic treatment
with SCSs dropped significantly from 52% to 32% (p<0.0001). With regard to physician’s care, the median
TABLE 1 Respiratory drug use in the 12 months preceding omalizumab initiation in asthma
patients in Belgium 2010–2016 (n=2068)
Asthma maintenance therapy
Patients on ICSs (with or without LABAs) 1943 (94%)
Patients on LABAs (with or without ICSs) 1917 (93%)
Number of DDs of ICSs (with or without LABAs) per year 240 (120–353)
Patients with at least one dispensing of a systemic corticosteroid 1757 (85%)
Number of DDDs of systemic corticosteroids per year 108 (58–256)
Patients on systemic corticosteroids as maintenance therapy (>180 DDDs per year) 648 (31%)
Patients on xanthines 340 (16%)
Patients on LTRAs 1.450 (70%)
Rescue medication
Number of DDDs SABAs+DDDs SAMAs (as rescue medication) 83 (25–267)
Use of long-acting bronchodilators other than LABAs
Patients on LAMAs 442 (21%)
Asthma burden
Patients being hospitalised in the past year with need of systemic corticosteroids 496 (24%)
Patients visiting ED in the past year with need of systemic corticosteroids 85 (4%)
Patients being hospitalised or visiting the ED in the past year with use of systemic
corticosteroids
502 (24%)
Data are presented as n (%) or median (interquartile range). As no defined daily doses (DDDs) are
provided by the World Health Organization for the fixed long-acting β2-agonist (LABA)+inhaled
corticosteroid (ICS) combinations, the number of daily doses (DDs) as described in the scientific notice are
provided. LTRA: leukotriene receptor antagonist; SABA: short-acting β2-agonist; SAMA: short-acting
muscarinic antagonist; LAMA: long-acting muscarinic antagonist; ED: emergency department.
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number of pulmonary physician consultations increased from three before treatment initiation to a
median number of nine consultations per year after initiation (p<0.0001).
Next, we investigated differences in asthma burden between patients who fulfilled eligibility criteria and
those who did not (table 3). The decrease in number of asthma exacerbations and in the proportion of
patients requiring chronic treatment with SCSs was more pronounced in patients fulfilling the eligibility
criteria versus those who did not (table 3). Indeed, the proportion of patients hospitalised for asthma in
the year before treatment initiation decreased from 41% to 21% in patients meeting the eligibility criteria,
whereas this decrease was only 5% (from 19% hospitalisations before initiation to 14% in the 1 year
following treatment initiation) in those who did not meet the eligibility criteria. Importantly, the
proportion of patients needing chronic treatment with SCSs decreased by 22% versus 8% respectively. A
similar pattern was observed for asthma-related ED visits (a decrease of 6% in patients meeting the
eligibility criteria versus 1% in those who did not). In patients eligible for omalizumab add-on treatment,
there was a small (−30 DDDs in the year following omalizumab) but significant decrease in ICSs use,
which might be partially due to the effectiveness of omalizumab as well as regression to the mean.
TABLE 2 Fulfilling eligibility criteria for omalizumab as add-on treatment in severe asthma
(equivalent to step 5 Global Initiative for Asthma treatment) (n=2068)
Patients with at least 274 DDs ICSs (with or without LABAs) in the past 12 months (A) 796 (38%)
Patients with at least 274 DDs LABAs (with or without ICSs) in the past 12 months (B) 710 (34%)
Patients with A and B 696 (34%)
Patients with at least two separate claims for systemic corticosteroids, at two different
dates (C)
1302 (63%)
Eligibility for add-on treatment with omalizumab in severe asthma:
Patients with A, B and C 497 (24%)
DD: daily dose; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist.
TABLE 3 Respiratory drug use and healthcare use in the 12 months preceding and in the 12 months following omalizumab
initiation (overall population and stratified into patients fulfilling eligibility criteria versus those who did not)
Patients initiating treatment with
omalizumab (n=1681)
Patients eligible for omalizumab
treatment (n=380)
Patients not eligible for
omalizumab treatment (n=1301)
YB YA YA−YB p-value YB YA YA−YB p-value YB YA YA−YB p-value
Patients visiting ED and
treated with SCS
68
(4%)
32
(2%)
−2% 0.0002# 34
(9%)
12
(3%)
−6% 0.0009# 34
(3%)
20
(2%)
−1% 0.0433#
Patients hospitalised and
treated with SCS
404
(24%)
258
(15%)
−9% <0.0001# 154
(41%)
78
(21%)
−20% <0.0001# 250
(19%)
180
(14%)
−5% <0.0001#
Patients treated with SCS
as maintenance
treatment (>180 DDD
per year)
520
(31%)
327
(19%)
−11% <0.0001# 220
(58%)
135
(36%)
−22% <0.0001# 300
(23%)
192
(15%)
−8% <0.0001#
DDD of respiratory drugs
per patient per year
median
ICS (with or without
LABA)
230 211 0 0.3981¶ 390 378 −30 0.0009¶ 180 180 0 0.2082¶
Rescue therapy (SABA
and/or SAMA)
85 67 0 <0.0002¶ 173 140 −6 0.2217¶ 75 50 0 0.0003¶
LTRAs 140 98 0 0.0528¶ 258 241 0 0.0334¶ 99 98 0 0.2998¶
Number of consultations
median
Pulmonary physician 3 9 4 <0.0001¶ 4 10 5 <0.0001¶ 3 8 4 <0.0001¶
Other physicians 6 5 0 0.0891¶ 13 12 −1 0.0249¶ 10 10 0 0.5037¶
YB: 12 months before omalizumab initiation; YA: 12 months after omalizumab initiation; ED: emergency department; SCS: systemic
corticosteroid; DDD: defined daily dose; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; SABA: short-acting β2-agonist; SAMA:
short-acting muscarinic antagonist; LTRA: leukotriene receptor antagonist. #: McNemar test; ¶: Wilcoxon rank-sum test.
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Of the 1681 patients with at least 1 year of follow-up data, only 976 (58%) were considered as compliant
and persistent users of omalizumab (defined as at least 10 monthly dispensings of omalizumab over
12 months of follow-up) in the year following treatment initiation. The median number of omalizumab
dispensings was 13 (interquartile range 9–22) (data not shown).
Cost and effectiveness of omalizumab
We compared the cost of one prevented hospitalisation in patients fulfilling the eligibility criteria versus
patients who did not (table 4). The total cost related to the use of omalizumab was divided by the number
of prevented hospitalisations. A decrease in hospitalisation was mainly observed in patients fulfilling the
eligibility criteria and the cost per prevented hospitalisation was much lower in those patients fulfilling
eligibility criteria (€44238 versus €139495) (table 4).
The mean annual cost per omalizumab-treated patient, 1 year before and 1 year after omalizumab
initiation is provided in table S3. From the data it is obvious that treating patients with omalizumab,
despite clear clinical benefits, did not result in a saving of healthcare costs, but rather in an increase, which
is more or less equivalent to the cost of omalizumab.
Mortality
Out of 1712 patients who initiated omalizumab, and for whom at least 1 year of follow-up was available,
31 (2%) died within the year following the index date. Mortality rates in patients following the first year of
omalizumab initiation were compared with the mortality rates of the Belgian population in 2014. From the
age and sex-specific mortality rates of the Belgian population, the number of expected deaths was derived
and from these data, the standardised mortality ratio (SMR) was calculated (table S2). The SMR was 2.33,
implying that the mortality rate in patients with uncontrolled severe asthma was 2.33 times higher than in
the general Belgian population of the same age and sex (table S2).
Discussion
We conducted a real-life, retrospective cohort study using claims data from the Belgian national social
security department to describe the characteristics of omalizumab use, focusing on eligibility criteria and
cost-effectiveness. We observed that fewer than three patients in 10 fulfilled the eligibility criteria for
omalizumab treatment, mainly due to nonadherence to high-dose ICSs and LABAs. The proportions of
patients requiring hospitalisation and/or needing chronic treatment with SCSs significantly decreased in
the year following treatment initiation and this reduction was the strongest in patients fulfilling the
eligibility criteria. The cost per prevented hospitalisation was threefold lower in patients fulfilling eligibility
criteria versus those who did not.
According to current GINA guidelines and the Belgian reimbursement criteria, omalizumab should be
reserved for patients with severe allergic asthma that remains uncontrolled despite chronic treatment with
high-dose ICSs in combination with LABAs (GINA treatment step 5) [7]. From our data we observed that
<30% of patients fulfilled eligibility criteria, which was mainly because of absence of chronic use of
medium or high-dose ICSs. Indeed, <40% of patients used ICSs during at least three-quarters of the
follow-up time; our Belgian data are in line with a recent publication highlighting low adherence to ICSs
(plus LABAs) in users of omalizumab in the USA [15].
Therefore, before omalizumab initiation, physicians should not only investigate asthma control, but should
also check adherence to asthma maintenance treatment (ICSs plus LABAs) as well as inhalation technique,
as these are known risk factors for lack of asthma control [16]. In clinical practice, however, it is difficult
TABLE 4 Cost to social insurance per prevented hospitalisation stratified into patients fulfilling
eligibility criteria for omalizumab initiation and those who did not
Patients eligible for
omalizumab treatment
Yes No
Number of patients 380 1301
Omalizumab cost in first year upon treatment initiation (a) €5087384 €15065429
Total number of hospitalisations in year prior to omalizumab initiation (b) 240 383
Total number of hospitalisations in year following omalizumab initiation (c) 125 275
Number of prevented hospitalisations since omalizumab initiation (d=b−c) 115 108
Cost per prevented hospitalisation (a/d) €44238 €139495
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to accurately estimate patient adherence to inhaled treatment, since anamnesis has been shown to be
unreliable. Accurate information on drug (such as ICSs plus LABAs) dispensing is very helpful, but
unfortunately not (yet) available to physicians in many countries (including Belgium). This was also
recognised in a recent review article on the cost-effectiveness of omalizumab underlying the importance of
objective measures of drug use and adherence to identify those patients who would optimally benefit from
add-on treatment with omalizumab [17].
Although our study is, to our knowledge, the first one to check eligibility criteria for omalizumab
treatment at a national level, similar results were described in a small cohort of asthma patients (n=24),
treated with omalizumab in Denmark between 2006 and 2015 [18]. This study reported that only 42% of
omalizumab-treated patients were appropriately selected according to current guidelines, mainly because of
inadequately reduced lung function, insufficient numbers of previous asthma exacerbations and asthma
treatment below GINA step 4–5. A Dutch study investigated treatment response in patients from the
Dutch national omalizumab registry and reported that eligibility criteria were met in 64% of
omalizumab-treated patients [19]. In contrast with our findings, this study could not identify a
relationship between fulfilling eligibility criteria and treatment response; however, in the Dutch study,
treatment response was based on the physician’s global evaluation of treatment effectiveness, which was
left to the discretion of the treating physician, whereas in our study, the response rate was evaluated by
hard outcomes such as ED visits and/or hospitalisations as well as dispensings of SCSs.
Of those patients initiating treatment with omalizumab and having at least 1 year of follow-up data, <60%
were compliant persistent users of omalizumab (defined as at least 10 monthly dispensings over 1 year).
Similar results have been reported by other studies with proportions of patients being consistent with
omalizumab treatment at 1 year follow-up ranging between 32% and 39% [20–22]. We do not have
information on the causes of noncompliance to omalizumab but we believe that it is a complex,
multicausal mechanism. Potential solutions to improve omalizumab compliance encompass setting up of
severe asthma clinical networks, thorough training on the appropriate use of omalizumab, optimisation of
asthma management strategies, where patients are involved as active partners, and finally selecting those
patients who are most likely to respond to the omalizumab treatment.
As for all observational studies, our study has strengths and weaknesses. The main strengths are the large
cohort size and completeness of data as we had access to all healthcare claims data encompassing drug
dispensing, medical services, hospitalisations and related costs. As information is collected on all Belgians
benefiting from social security (99% of the population), the potential for selection bias is negligible and
external validity is high.
A first limitation of the study is the lack of information on covariates, such as lifestyle, comorbidities and
indication of use. Omalizumab is indicated for the treatment of severe allergic asthma and for chronic
idiopathic urticaria, and is prescribed by respiratory physicians or dermatologists, respectively. Because of
the absence of clinical data in the Belgian claims database, a proxy for asthma-related hospitalisation/ED
visits was defined that consisted of hospitalisations/ED visits in combination with the use of SCSs. This
might potentially result in an overestimation of asthma-related ED visits/hospitalisations in patients with
asthma and other inflammatory conditions (e.g. rheumatoid arthritis, Crohn’s disease), where disease
flare-ups are also treated with SCSs. If present, the chance of this bias would be identical before and after
treatment initiation, implying that our results would remain valid. Second, chronic use of ICSs (with or
without LABAs) was defined as use of ICSs during at least 75% of the follow-up time. This implies that we
underestimated the proportion of patients not meeting omalizumab eligibility criteria as, strictly speaking,
100% of follow-up time should be covered by the use of these drugs. Third, in our study, maintenance
treatment of systemic steroids was defined as the use of at least 180 DDDs in a period of 12 months. This
definition might have been too strict and might have underestimated the number of patients on chronic
treatment with systemic steroids [23]. In a sensitivity analysis, chronic use of systemic steroids was defined
as at least 90 DDDs in a period of 12 months which resulted in similar findings with regard to treatment
response following omalizumab initiation (data not shown). Fourth, <60% of patients were compliant
persistent users of omalizumab (defined as at least 10 monthly dispensings of omalizumab over 12 months
of follow-up) in the year following treatment initiation. In Belgium, the treatment response to omalizumab
has to be evaluated by the treating respiratory physician after 16 weeks of treatment; in a subgroup of
patients omalizumab treatment is discontinued at the re-evaluation because of side effects or lack of
treatment response. Since we do not have information regarding the cause of treatment discontinuation,
we cannot distinguish between patients who were strictly noncompliant to omalizumab treatment and
those patients in whom omalizumab was discontinued due to a lack of treatment response. Fifth, we might
have overestimated actual use of asthma drugs, as the database contains information on drug dispensing,
but not on actual use or correct (inhaler) use. Finally, as information on lab data (for IgE), spirometry
data as well as information on asthma control was missing, we were not able to investigate whether the
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additional eligibility criteria for omalizumab were met. Again, having these data would imply that the
proportion of patients not fulfilling eligibility criteria would even be higher than we reported.
Despite these limitations, we do believe that the main findings of this study are robust. First, the majority
of patients on omalizumab in Belgium did not meet the eligibility criteria. It can be assumed that for up
to 75% of the patients treated with omalizumab, improved asthma management, encompassing chronic
treatment with asthma controller therapy (i.e. high-dose ICSs/LABAs), optimised adherence and improved
inhaler technique, might have achieved better asthma control, obviating the need for add-on therapy with
expensive biologics [24]. Second, omalizumab was effective in reducing hospitalisations and the use of SCSs,
but treatment response (in terms of absolute risk reduction and cost-effectiveness) was much lower if
eligibility criteria were not met. Careful identification of patients meeting eligibility criteria for omalizumab
should be a priority for prescribers, where access to pharmacy dispensing data of (inhaled) drugs would be
of ultimate value to differentiate between difficult-to-treat asthma (due to nonadherence to ICSs + LABAs)
and uncontrolled severe asthma. Third, clinical benefits with omalizumab were achieved at a high cost that
was higher in patients who did not fulfil the eligibility criteria compared with patients fulfilling the
criteria. Moreover, add-on treatment with omalizumab did not result in any saving to health insurance but
rather in an increase in total healthcare costs per patient, equivalent to the cost of omalizumab. Our data
are in line with a recent cost-effectiveness study which computed a cost of USD 313000 per quality-adjusted
life-year gained for omalizumab treatment. The authors of this study concluded that at its current price,
omalizumab was not cost-effective [25].
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